MDxHealth and LI PATH Announce Marketing Agreement for ConfirmMDx for Prostate Cancer

MDxHealth and LI PATH Announce Marketing Agreement for ConfirmMDx for Prostate

IRVINE, Calif.  and  HERSTAL,  Belgium,  April 2,  2014  (GLOBE  NEWSWIRE)  -- 
MDxHealth SA (NYSE  Euronext: MDXH),  a leading  molecular diagnostic  company 
that develops and commercializes epigenetic tests to improve the diagnosis and
treatment of  cancer patients,  today announced  that it  has entered  into  a 
co-marketing agreement with LI PATH  (Long Island Pathology, Inc.) to  promote 
MDxHealth's ConfirmMDx^®  for Prostate  Cancer test.  LI PATH  is a  high-end, 
full-service independent  anatomic  and  clinical  pathology  laboratory  that 
serves the New York City metropolitan area. The agreement expands MDxHealth's
access to urologists in the highly populated New York and New Jersey region.

"Our goal is to be the premier laboratory serving the urology community in the
New York City area,  and offering the most  advanced molecular testing to  our 
urology clients is  an important part  of that equation,"  stated Ken  Cerney, 
Chief Executive Officer of LI PATH. "The ConfirmMDx for Prostate Cancer test
provides actionable information to help urologists better stratify patients at
risk for undetected prostate cancer and guide the decision for repeat  biopsy. 
The addition ConfirmMDx  to our portfolio  of tests enhances  our ability  to 
serve our clients."

"We are excited to announce our strategic partnership with LI PATH, recognized
as a  leading anatomic  and  clinical pathology  laboratory  in the  New  York 
metropolitan region. With their extensive client base and strong  reputation, 
the partnership further expands access  to our ConfirmMDx for Prostate  Cancer 
test within this  important geographic  region," said  Dr. Jan  Groen, CEO  of 
MDxHealth. "It is rewarding to  partner with progressive thinking  laboratory 
professionals like LI PATH, who are focused on leveraging molecular diagnostic
tests to deliver the highest quality patient care."

About ConfirmMDx® for Prostate Cancer
Over 975,000 American men receive a negative prostate biopsy result each year,
though approximately 25% of these men may still harbor occult prostate cancer.
This  well-documented  risk  of  undetected  cancer,  often  with   clinically 
significant Gleason  scores, leads  to a  high rate  of repeat  biopsies  with 
greater than  40%  of men  receiving  at least  one  repeat biopsy,  and  many 
receiving a 3rd and 4th biopsy. Today's gold standard diagnostic approach  is 
the prostate biopsy  procedure, collecting 10-12  needle core biopsy  samples; 
however this sampling represents less than 1% of a man's prostate. ConfirmMDx
for Prostate  Cancer is  an epigenetic  assay to  help urologists  distinguish 
patients who have a true-negative biopsy from those at risk for occult cancer.
The test is able  to detect an epigenetic  field effect or "halo"  associated 
with the cancerization process at the DNA level. This molecular "halo" around
a cancer lesion can  be present despite having  a normal appearance under  the 
microscope. The test helps urologists rule out prostate cancer-free men  from 
undergoing unnecessary repeat biopsies and rule in high-risk patients who  may 
require repeat biopsies and potential treatment.

LI PATH is a premier diagnostic and consultative anatomical laboratory located
in East Setauket, New  York that has been  serving the regional community  for 
nearly 20  years.LI PATH  is dedicated  to providing  top-level  diagnostic 
pathology and clinical services in a cost effective and efficient manner. The
laboratory's pathologists are  certified by  the American  Board of  Pathology 
with  multiple  areas  of  sub-specialties  and  are  active  members  of  the 
community.  For  additional  information  about  LI  PATH's  clinical  and  AP 
diagnostic offerings, please visit

About MDxHealth
MDxHealth is a molecular diagnostics company that develops and  commercializes 
advanced epigenetic tests for cancer assessment and the personalized treatment
of patients. MDxHealth  helps to address  a large and  growing unmet  medical 
need for better cancer diagnosis and treatment information. The company has  a 
proprietary platform and a strong  epigenetic product pipeline focused on  the 
development of products for  prostate, brain, bladder  and lung cancers.  For 
more  information   visit   and   follow  us   on   Twitter

For more information:

Dr. Jan Groen, CEO  Mike Sinclair         Len Hall
MDxHealth           Halsin Partners       Allen & Caron, Inc
US: +1 949 812 6979 UK: +44 20 7318 2955 US: +1 949 474 4300
BE: +32 4 364 20 70 Cell: +44 7968 022075  

This press  release contains  forward-looking  statements and  estimates  with 
respect to the anticipated future performance  of MDxHealth and the market  in 
which it operates. Such statements and estimates are based on assumptions  and 
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable  but may  not prove to  be correct.  Actual events  are 
difficult to predict, may  depend upon factors that  are beyond the  company's 
control, and  may turn  out to  be materially  different. MDxHealth  expressly 
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in  its expectations with regard thereto or  any 
change in events, conditions or circumstances  on which any such statement  is 
based unless  required by  law  or regulation.  This  press release  does  not 
constitute an offer or  invitation for the sale  or purchase of securities  or 
assets of MDxHealth  in any jurisdiction.  No securities of  MDxHealth may  be 
offered or sold within the United  States without registration under the  U.S. 
Securities Act  of  1933, as  amended,  or  in compliance  with  an  exemption 
therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are  trademarks 
or registered trademarks  of MDxHealth  SA. All other  trademarks and  service 
marks are the property of their respective owners.

To access the PDF version, please click here

Press spacebar to pause and continue. Press esc to stop.